BRIEF—Cipla partners with MSN Laboratories on generic Xeloda

The US subsidiary of Indian drugmaker Cipla has secured rights from MSN Laboratories to market and distribute capecitabine 150mg and 500mg tablets in the USA.

The product is available immediately.

The capecitabine tablet is an AB-rated generic therapeutic equivalent version of Roche affiliate Genentech’s Xeloda.

Capecitabine is indicated as a single agent for adjuvant treatment in patients with Dukes C colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred, and also indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy.

As per IQVIA (formerly IMS Health), Xeloda and its generic equivalents had US sales of around $178 million for the 12-month period ending June 2018.